Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Invitation to Cereno Scientific webcast: Clinical Phase II study with drug candidate CS1 in PAH

Cereno Scientific (XSAT: CRNO B) invites investors, financial analysts, and media to a webcast presentation on February 25, 2022. The presentation will focus on the Phase II study of drug candidate CS1 in the rare disease pulmonary arterial hypertension (PAH). Chief Executive Officer, Sten R. Sörensen and Chief Medical Officer Dr. Björn Dahlöf from Cereno will be joined by Dr. Raymond Benza, Principal Investigator for the study and Dr. Philip Adamson, Vice President and Chief Medical Officer at study collaborator Abbott.  The presentations will cover the background, design, and plan for the

SAPA Series with Emma Ridderstad

It was not so long ago that parallel worlds were merely the staple of science fiction writers. Today however, the nascent technology of virtual and augmented reality is for the first time making it possible to talk about the merging of the digital and physical into a single, hybrid universe. Propelled by the booming gaming sector, virtual reality has in the last few years started to spill over into industries ranging from education and human resources, to construction and design. And yet, more than half a century after the very first VR headset was created in the US for military

DSRT: Desert Control H2 2021 Report and interim Financial Results | Webcast presentation 25 February 10:00 CET

ISSUER DESERT CONTROL AS Desert Control H2 2021 Report and Financial Results will be released on Friday25 February 2021 at 0800 AM Central European Time (Oslo).Report and presentation will be available at www.desertcontrol.comWebcast presentation in English will be hosted on Friday 25 February at 10.00 AMCentral European Time.Registration:https://desertcontrol.zoom.us/webinar/register/7816451668620/WN_gNoNVqAgSH6UrdqhZbkjwwAfter the presentation, there will be a moderated question and answers session.Questions for Q&A can be submitted in advance toerling.rasmussen@

Scandinavian ChemoTech’s subsidiary signs its first commercial contract for the US veterinary market

ChemoTech’s Animal Care division Vetiqure AB signs a contract with FloridaWild Veterinary Hospital (“FloridaWild”) in Deland, Florida as a direct result of a successful trade show in Orlando, which generated many leads.The contract with FloridaWild includes access to our vetIQure™ TSE device during an initial evaluation period and a commercial purchase of our treatment kits. In addition to the purchase of the treatment kits an order for the device will be placed following a successful evaluation. The joint goal with the agreement is to establish a Centre of Excellence with FloridaWild where

Inhalation Sciences signs IRS contract worth 584,000 SEK with leading nanotech company

Inhalation Research Services, ISAB’s contract research organization, has signed a contract worth 584 000 SEK with a leading nanotechnology company that specializes in developing new inhalable nanoporous particles for drug delivery. The client has chosen ISAB’s unique intratracheal in vivo exposure module for its research project, due to its proven precision and reliability.The development of nanoparticles for drug delivery is a fast-moving and high-potential research area within the pharmaceutical industry. A leading company in the field has now chosen Inhalation Research Services for a

Hynion and Hyrex launches floating hydrogen station for leisure boats

Hynion AS and Hyrex AS last year set up a JV for establishing hydrogen stations for refuelling leisure boats with zero-emission fuel, and are now presenting innovative fueling solutions.- Hydrogen will be important for the decarbonisation of the transport sector in Norway, not least in the maritime sector. Although other modes of transport account for larger emissions than leisure boats, this is a significant segment. The Norwegian authorities have given clear signals that emissions from leisure boats should be reduced by 50 %. The establishment of floating hydrogen stations will improve

BioStock: Strong start to 2022 for Respiratorius

2022 looks to be an eventful year for Lund-based Respiratorius, which released its report for the fourth quarter on Tuesday. The company has started the PK study with the new formulation of VAL001, while announcing a new capital injection and plans to spin off its respiratory project. BioStock contacted the company's CEO Johan Drott to dig a little deeper into the quarterly report and get his view on the interesting situation the company is in at the moment.Read the full interview with Johan Drott at biostock.se: https://www.biostock.se/en/2022/02/strong-start-to-2022-for-respiratorius/

Hired a creative director before the upcoming global launch of Cricket Manager Pro

on February 18, 2022 at 08:30 Wicket Gaming AB (publ) has hired Philip Cederman as the new Creative Director. Philip Cederman is especially hand-picked ahead of the upcoming global launch of Cricket Manager Pro.Philip comes most recently from Mud Studios, where he has worked for the past 4 years as Technical Director, Group Leader and Retouch Artist. He has over 10 years of experience in IT technical roles as well as graphic design and leadership. At Wicket Gaming, Philip will, among other things, work to raise the graphic profile for Wicket Gaming and the company's products, which

Year-End Report October – December 2021

(Oslo, 18 February 2022) Genetic Analysis AS (“GA” or “the Company”) hereby publishes the year-end report for the period 1 October – December 31, 2021. The year-end report is available as an attached file to this release and on the Company’s website. Below is a summary of the report.Genetic Analysis CEO Ronny Hermansen comments:“The year of 2021 has passed, and we can look back on an eventful year filled with milestones like an oversubscribed IPO, successful listing at Spotlight Stock Market, the signing of IMD as a new high-volume lab in Europe, and the receival of a research grant of

ORGANOCLICK AB (PUBL) PUBLISH YEAR END REPORT FOR 2021

"Sales of OrganoTex® more than doubled during the quarter, as with the full year. We expect the very strong sales growth of OrganoTex® to continue in 2022, driven by all our new customers and ongoing international expansion."Translation from CEO Mårten Hellbergs comments to the Interim Report. Q4, 1 October - 31 December 2021 The Group compared with 2020 » Net revenue amounted to SEK 17.95 (18.20) million » The gross margin (after variable costs) amounted to 43.8 (40.9) % » EBITDA amounted to SEK -7.65 (-6.03) million » Cash-flow from operating activities amounted to SEK -

Year-end report January – December 2021

The period in summary January 1 – December 31, 2021 –      The European Commission granted in August a Marketing Authorisation for Strangvac within the European Union. During September the Veterinary Medicines Directorate (VMD) of the United Kingdom also granted a Marketing Authorisation for Strangvac within the UK. –      In April Intervacc announced an exclusive distribution agreement with Dechra Pharmaceuticals PLC, to commercialize Strangvac in Europe, excluding the Nordic and Baltic countries where Intervacc will market and sell Strangvac directly. –      Intervacc was

Episurf Medical’s implants receive national regulatory approval in Hong Kong

Episurf Medical (NASDAQ: EPIS B) today announces that the Department of Health (Medical Device Division) in Hong Kong has approved the company’s implant technologies Episealer® Knee and Episealer® Talus for the Hong Kong market. Included in the approval is also the ankle device Talus Osteotomy Guide. The approval follows a review process.  “Previously we were able to act in this market thanks to our CE marked products, but it brought on various limitations. This national approval is important, and it will help us increase the market acceptance in the region even further”, says Michael

Notice of the Annual General Meeting of Ratos AB (publ)

Shareholders of Ratos AB (publ), reg.nr 556008-3585, are hereby invited to the Annual General Meeting to be held at Tuesday, March 22, 2022. The AGM will be conducted pursuant to so called mail-in procedures, meaning that no shareholders will attend the AGM in person or through proxy. Instead, shareholders can participate in the AGM by voting and submitting questions in advance pursuant to the instructions described below.In order to participate in the AGM, a shareholder shall:   a. be registered in the register of shareholders maintained by Euroclear Sweden AB as of Monday, March 14,

Veoneer publishes 2021 Annual and Sustainability Reports

Stockholm, Sweden, February 18, 2022: The automotive technology company Veoneer, Inc. (NYSE: VNE and SSE: VNE SDB), has filed its 2021 Annual Report on Form 10-K with the Securities and Exchange Commission (SEC).The 2021 Annual Report on Form 10-K is available at the SEC Edgar website: www.sec.gov and on Veoneer’s web site veoneer.com. Veoneer has also published its 2021 Sustainability Report and it is available on Veoneer’s web site veoneer.com. Annual Meeting of ShareholdersThe Board of Directors has set June 2, 2022 as the date for Veoneer's 2022 Annual Meeting of Shareholders to be

Attana has submitted a new patent application

Attana has filed a new patent application with claims for methods for assessing the neutralising potential of antibodies in biological samples. The invention is applicable in both of Attana´s business areas – Life Science and Diagnostics.Attana has filed a new patent application with several claims assessing the neutralising potential of antibodies or other biological entities in complex biological samples. The invention can be applied within diagnostics with the purpose to better determine the immunity of individuals based on several parameters, such as kinetics and titres of immune

Invitation to presentation of Sectra’s nine-month interim report 2021/2022

Linköping, Sweden – February 18, 2022 – International medical imaging IT and cybersecurity company Sectra  (STO: SECT B) invites investors, analysts, and the media to a presentation of the company’s nine-month report with President Torbjörn Kronander and CFO Mats Franzén.Publication of the interim report: 8:15 a.m. (CET) on March 9, 2022Report presentation: 10:00 a.m. (CET) on the same date To participate, follow the instructions on Sectra’s website investor.sectra.com/Q3report2122.The broadcast will also be made available on the same webpage after the conference.

Greenfood wins prestige business award - recognized for excellence in sustainability and innovation

Greenfood has won the Swedish business award, Företagsstjärnan (Star Company). The prize was awarded for Greenfood's outstanding performance in providing the market with sustainable, plant-based, affordable, and easily accessible food.“The climate is the most important issue of our time. How we produce our food and what we eat has major effects on the climate and the environment, so we must do everything we can to accelerate the transition to plant-based alternatives,” said David von Laskowski, President and CEO of Greenfood Group. Greenfood is one of northern Europe's leading players

Cell Impact reports fourth quarter results: increased sales

Cell Impact AB (Nasdaq First North GM: CI B) reports the following financial summary for the fourth quarter.· Revenues for the quarter amounted to SEK 21.0 million (8.9). Total revenues up to and including the fourth quarter amounted to SEK 81.8 million (29.3), which is growth of 179% for the entire year. · Operating result was SEK -25.7 million (-12.3). Total operating result was SEK -78.0 million up to and including the fourth quarter (-43.1). · The Group's result after financial items was SEK -26.5 million (-12.5). · Earnings per share attributable to the shareholders of the

Autoliv provides exterior airbag for Nuro’s autonomous vehicle

(Stockholm, Sweden, February 18, 2022) – Autoliv, Inc. (NYSE: ALV and SSE: ALIV.sdb), the worldwide leader in automotive safety systems, and Nuro, a leading autonomous vehicle company, are collaborating to ensure a high safety standard for Nuro’s new third-generation, production-grade autonomous delivery vehicle.As the most advanced zero-occupant vehicle designed by Nuro to date, the new flagship model features an exterior airbag by Autoliv which covers the front of the vehicle when inflated to protect other road users. The third-generation vehicle, simply called Nuro, is expected to scale

Arla Plast AB Year-end report 2021

Lower margins in the Quarter – Full year in line with financial objectivesOCTOBER – DECEmber 2021 · Sales volume declined by 2% to 5,503 tonnes (5,588). · Net sales increased by 13% to SEK 240.3 (211.9) million. The organic increase was 12%. · Operating profit declined by 63% to SEK 10.2 (27.4) million and adjusted operating profit by 69% to SEK 10.2 (33.2) million. · The operating margin declined to 4.2% (12.9%) and adjusted operating margin declined to 4.2% (15.7%).  · Profit for the period declined by 58% to SEK 8.4 (19.9) million. · Earnings per share before dilution

Adam & Albin to open Nori Bar in Bibliotekstan

Adam & Albin, together with multi-award-winning Josephine Sondlo, are to open Nori Bar in Birger Jarlspassagen. The new cocktail bar will open during spring in a space of almost 100 sqm with the ambition of further strengthening the prestigious Birger Jarlspassagen walkway as a vibrant meeting place at the heart of the city.Adam & Albin already run the Misshumasshu restaurant in Birger Jarlspassagen, which will now be completed by the cocktail bar with the celebrated chef duo and star bartender Josephine Sondlo. The inspiration for the Nori Bar concept is taken from the best New York bars

Viking Line: Year-End Report January - December 2021

Viking Line Abp                  YEAR-END REPORT              18.02.2022, 9.00 AM           January– December 2021 (compared to January–December 2020) · Sales amounted to EUR 258.2 M (EUR 188.8 M). · Other operating revenue was EUR 46.8 M (EUR 26.9 M). · Operating income totalled EUR 32.1 M (EUR -49.3 M). · Net financial items were EUR -3.8 M (EUR -3.6 M). · Income before taxes amounted to EUR 28.3 M (EUR -52.9 M). · Income after taxes totalled EUR 24.4 M (EUR -42.3 M). Outlook for the financial year 2022 The COVID-19 pandemic continues to have an impact on

Recipharm expands its advanced therapy medicinal products (ATMPs) offering into Virotherapies with the acquisition of Vibalogics

Recipharm, a global contract development and manufacturing organisation (CDMO), is continuing to build its service offerings in new biologic modalities through the acquisition of Vibalogics, a virotherapy CDMO and a portfolio company of Ampersand Capital Partners. Vibalogics holds a leading position in the manufacture of oncolytic viruses, viral vaccines and gene therapies, offering process and analytical development, manufacturing, testing and fill-finish services. Vibalogics is responding to the rapidly growing biopharmaceutical industry demand for specialized CDMO capabilities for the

There are no items matching the current filter
There are no more items matching the current filter
Back to top